Cullinan Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Recent Form 8-K reports furnish operating results and financial-condition updates, Regulation FD materials, and clinical disclosures tied to programs including CLN-978, CLN-049 and zipalertinib.
The filing record also covers corporate and governance matters, including definitive proxy disclosures on executive and director compensation, equity awards and shareholder voting matters. Material-event filings document portfolio and contractual actions, including the termination of an exclusive patent license related to CLN-617 through Cullinan Amber Corp.
Cullinan Therapeutics ownership disclosure by Kynam Capital group. The filing reports that Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang beneficially own 3,114,132 shares of Cullinan Therapeutics common stock, equal to 5.27% of the class as of 12/31/2025.
The disclosure lists shared voting and dispositive power of 3,114,132 shares and zero sole voting or dispositive power. The report includes the issuer CUSIP 230031106 and the filer address in Princeton, New Jersey.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of 1,780 shares of common stock at a weighted average price of $14.14 per share. After this transaction, she directly holds 174,844 shares of Cullinan Therapeutics common stock.
The sale was effected under a pre-arranged trading plan established pursuant to Rule 10b5-1 on August 7, 2025. The reported price reflects a weighted average for multiple trades executed between $13.89 and $14.35 per share.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported selling a total of 5,353 shares of common stock in open-market transactions. She sold 3,601 shares on February 24, 2026 at a weighted average price of $14.47 per share and 1,752 shares on February 23, 2026 at a weighted average price of $13.99 per share. These sales were effected under a Rule 10b5-1 trading plan and were described as covering personal income tax obligations upon vesting of restricted stock units. After the transactions, she directly holds 176,624 Cullinan Therapeutics common shares.
Cullinan Therapeutics reported that President and CEO Nadim Ahmed executed an open-market sale of 13,515 shares of common stock at $14.47 per share. According to the filing, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, he directly owned 390,803 shares.
Cullinan Therapeutics Chief Medical Officer Jeffrey Alan Jones reported an open-market sale of 4,582 shares of common stock at $14.47 per share. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, Jones directly holds 159,968 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics, Inc. Chief Legal Officer Jacquelyn L. Sumer reported an open-market sale of 3,601 shares of common stock at $14.47 per share on February 24, 2026. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly owned 128,089 shares.
Jennifer Michaelson reported multiple 10b5-1 sales of common stock under Form 144, covering transactions from 12/12/2025 through 02/23/2026. The filing lists several dispositions, including 8,000 shares on 02/20/2026 and 1,752 shares on 02/23/2026.
Cullinan Therapeutics Chief Medical Officer trades shares to cover taxes. Jeffrey Alan Jones reported an open-market sale of 4,982 shares of common stock at $13.62 per share on February 20, 2026, to cover personal income tax obligations upon vesting of restricted stock units, and now holds 164,550 shares directly.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported multiple equity transactions in company stock. On February 20, 2026, she exercised stock options for 8,000 shares of common stock at a stated exercise price of $4.30 per share, reflected through derivative and non-derivative entries. She then sold a total of 11,742 shares of common stock in open-market transactions at prices of $13.62 and $14.30 per share. A footnote states that a portion of the sales was made to cover personal income tax obligations upon vesting of restricted stock units and that the transactions were effected under a Rule 10b5-1 trading plan established on August 7, 2025. Following these transactions, her reported direct ownership remained in the range of approximately 180,000–190,000 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics Chief Legal Officer sells shares for taxes. Jacquelyn L. Sumer executed an open-market sale of 3,742 shares of Cullinan Therapeutics common stock at $13.62 per share on February 20, 2026 to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly holds 131,690 shares.